Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02929589 · ClinicalTrials.gov registry record · Phase 3

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

A Phase 3 study, sponsored by Mike O'Callaghan Military Hospital.

Terminated
Registry status
Phase 3
Development phase
18
Enrollment target

NCT02929589: Clinical Trial Phase 3 study, sponsored by Mike O'Callaghan Military Hospital.

NCT02929589 is a Phase 3 study that was terminated before completion, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 18 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02929589, a Phase 3 study, was terminated before completion, sponsored by Mike O'Callaghan Military Hospital.

TERMINATED
Registry status
Phase 3
Development phase
18 participants
Enrollment target

Study Summary

This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued. The patients will not be allowed to continue any over-the-counter pain medications, such as ibuprofen, naproxen, or acetaminophen containing medications, that were not prescribed by the investigators during this study. Patients not receiving Ibuprofen will be given a placebo pill composed of corn starch. The placebo pill will be formulated into the same shape, size and color as the ibuprofen capsule. Neither the investigators nor the research subjects will know if the subject is receiving a placebo versus Ibuprofen. The subjects will complete pain level and medication diaries, and will be followed for 2 months after their surgery. The research aims to discover the appropriate amount of opioid medication to prescribe to patients undergoing an elective open inguinal hernia repair, and reduce the total opioid dose needed by utilizing ibuprofen in combination. The investigators expect that the subjects who take ibuprofen will use less oxycodone/acetaminophen, and have comparable or lower mean pain levels. This could contribute to reducing the surplus opioids prescribed by physicians after surgery, which can lead to opioid use disorders. This particular procedure is common in men, and the findings have the potential to decrease the symptoms and pain of Active Duty members and DoD beneficiaries who undergo an inguinal hernia repair, and are at risk for prescription drug abuse or dependence.

Primary Outcome

The primary outcome measure was milligram morphine equivalent units to measure pain intensity difference and total pain relief.

Interventions

  • DRUG Placebo
  • DRUG Ibuprofen
  • DRUG Opioid Medication
  • DRUG Ibuprofen + Opioid medication

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-07-05
Est. Completion 2021-08-23
Phase Phase 3
Mike O'Callaghan Military Hospital

26 total trials

Why NCT02929589 stopped before completion

NCT02929589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT02929589 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02929589 about?

NCT02929589 is a clinical study titled "Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy". This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, h...

What is the current status of trial NCT02929589?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2018-07-05. Estimated completion is 2021-08-23.

What interventions are being tested in trial NCT02929589?

The interventions under investigation include: Placebo (DRUG), Ibuprofen (DRUG), Opioid Medication (DRUG), Ibuprofen + Opioid medication (DRUG).

Who is sponsoring clinical trial NCT02929589?

This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02929589's enrollment target sits among peer trials

18 1970th of 2000 higher than 30 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02929589, the US trial registry maintained by the National Library of Medicine. NCT02929589 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.